Investigating how specific proteins affect spleen development in fetal cells
Official title: Specificity of RPSA-dependent translational control in mouse and human fetal spleen cells
Funded at University of California, San Francisco · NIH-10647605 · Data updated 2026-11-12
This study is looking at how a protein called RPSA affects the development of the spleen in people with Isolated Congenital Asplenia, a condition where the spleen is missing or not fully formed, to help us understand how this might impact their immune system.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $161,500 |
| NIH project number | 1R03HD111800-01 |
| Project ID | NIH-10647605 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Isolated Congenital Asplenia or those with genetic mutations affecting ribosome function.
✕Less likely to help
Patients without congenital asplenia or those not affected by ribosomopathies may not benefit from this research.
What this research studies
This research focuses on understanding ribosomopathies, which are disorders caused by genetic abnormalities affecting ribosome function. It specifically examines the role of the RPSA protein in the development of the spleen, particularly in patients with Isolated Congenital Asplenia (ICA), a condition where the spleen is absent or underdeveloped. By studying mouse and human fetal spleen cells, the research aims to uncover how deficiencies in RPSA impact spleen development and function, which is crucial for the immune response. The methodology includes generating specific cell models to analyze the effects of RPSA mutations on spleen cell development.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and potential treatments for congenital asplenia and related disorders.
How similar studies have gone: Previous research has shown promising results in understanding ribosomopathies, indicating that this approach may yield valuable insights.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Selleri, Licia — University of California, San Francisco
- Study coordinator: Selleri, Licia
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.